- Home
- A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
This symposium emphasises the critical role of accurate and rapid diagnosis in enabling physicians to quickly start guideline-directed medical therapy. Prof Antoni Bayes-Genis (University Hospital Germans Trias i Pujol, Barcelona, ES), Dr Lisa Anderson (St George's Hospital, London, UK) and Dr Stephen Greene (Duke University School of Medicine, Durham, US) discuss and reflect on current guidelines and emerging algorithms, offering insights into the challenges surrounding delays and adoption rates in both community and hospital settings and their profound impact on patient care.
Presented, and recorded, at HFA 2024 in Lisbon, PT
Support Statement
This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.
Target Audience
- Cardiologists
- Heart Failure Specialists
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| 1 | Welcome and Introduction | 4m 44s | Lisa Anderson |
| 2 | Implementing GDMT: What Should We Be Doing? | 15m 59s | Antoni Bayés-Genís |
| 3 | Implementing GDMT: What Is Really Happening? | 17m 13s | Lisa Anderson |
| 4 | The Implication of Delayed Diagnosis and Sub-Optimal GDMT | 14m 13s | Stephen J Greene |
| 5 | Panel Discussion & Audience Q&A - Accelerating the Adoption Of GDMT | 2m 32s | Antoni Bayés-Genís |
| 6 | Key Take-Home Messages and Close | 43s | Antoni Bayés-Genís |
The Implication of Delayed Diagnosis and Sub-Optimal GDMT
Duration: 14m 13s
Speakers: Stephen J Greene
Panel Discussion & Audience Q&A - Accelerating the Adoption Of GDMT
Duration: 2m 32s
Speakers: Antoni Bayés-Genís
Related Courses
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients